Riskpilot← Back to searchSign inGet full accessNipro Nordics AB
ABActiveOrg 5569223141StockholmWholesale of pharmaceutical and medical goods · NACE 4646Est. 201310-19 employees
Revenue 2024
SEK 5M
+113% vs 2023
EBITDA margin
6.3%
+115% vs 2023
Equity ratio
43.2%
Financial strength
Net profit 2024
SEK 288K
+75% vs 2023
| Revenue | SEK 5M | +113% |
| EBITDA | SEK 318K | +115% |
| Net profit | SEK 288K | +75% |
| Total assets | SEK 1,4M | +147% |
| Equity | SEK 599K | +93% |
| Employees | — | — |
Legal name
Nipro Nordics AB
Org number
5569223141
Legal form
Aktiebolag
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
12 februari 2013
Share capital
SEK 50 000
Employees
10-19
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget skall bedriva försäljning och marknadsföring av medicin- tekniska produkter samt därmed förenlig verksamhet.
Address
Stockholm
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 6 | 1 584 | 2 069 | 2 364 | 5 033 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −60 | 19 | 41 | 148 | 318 |
| Depreciation & amort. | −1 | −0 | −2 | −3 | −30 |
| EBIT | −61 | 19 | 39 | 145 | 288 |
| Net financials | — | — | −13 | 20 | — |
| Profit before tax | −61 | 19 | 26 | 165 | 288 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −61 | 19 | 26 | 165 | 288 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 446 | 485 | 993 | 562 | 1 388 |
| Equity | −86 | 120 | 146 | 310 | 599 |
| Long-term debt | 0 | 0 | 0 | 0 | 59 |
| Short-term debt | 532 | 366 | 847 | 252 | 730 |
| Total debt | 532 | 366 | 847 | 252 | 789 |
EBITDA margin
6.3%
This company
15.8%
Market median
-60% vs market
20202024
Equity ratio
43.2%
This company
38.2%
Market median
+13% vs market
20202024
Return on equity
48.1%
This company
18.4%
Market median
+161% vs market
20202024
Net profit margin
5.7%
This company
8.1%
Market median
-30% vs market
20202024
Asset turnover
3.63×
This company
1.12×
Market median
+224% vs market
20202024
Debt / equity
1.32×
This company
0.62×
Market median
-113% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
JA Authorized Recipient of Service | Authorized Recipient of Service | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2022 | |
| Board of Directors | 2022 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2025 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
NIPRO MEDICAL EUROPE N.V
Nipro Nordics AB (this company)Board members of Nipro Nordics AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Jens Axel André | Authorized Recipient of Service | 0 companies |
| Tomoshiro Somekawa | Deputy Board Member | 0 companies |
| Serge Yvonne K Kemps | Board of Directors | 0 companies |